Ignite Creation Date:
2025-12-24 @ 2:45 PM
Ignite Modification Date:
2025-12-27 @ 9:29 AM
Study NCT ID:
NCT07220759
Status:
RECRUITING
Last Update Posted:
2025-12-23
First Post:
2025-10-23
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D050177', 'term': 'Overweight'}, {'id': 'D009765', 'term': 'Obesity'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044343', 'term': 'Overnutrition'}, {'id': 'D009748', 'term': 'Nutrition Disorders'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D001835', 'term': 'Body Weight'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000717792', 'term': 'cagrilintide'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR'], 'maskingDescription': 'Sponsor staff involved in the clinical trial is masked according to company standard procedures.'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 330}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2025-11-05', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-12', 'completionDateStruct': {'date': '2027-07-28', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-12-22', 'studyFirstSubmitDate': '2025-10-23', 'studyFirstSubmitQcDate': '2025-10-23', 'lastUpdatePostDateStruct': {'date': '2025-12-23', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2025-10-24', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2027-06-09', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Relative change in body weight', 'timeFrame': 'From baseline (week 0) to end of treatment (week 64)', 'description': 'Measured as percentage (%) of body weight.'}, {'measure': 'Number of participants with achievement of greater than or equals (>=) 5% body weight reduction', 'timeFrame': 'From baseline (week 0) to end of treatment (week 64)', 'description': 'Measured as count of participants.'}], 'secondaryOutcomes': [{'measure': 'Number of participants with achievement of >= 10% body weight reduction', 'timeFrame': 'From baseline (week 0) to end of treatment (week 64)', 'description': 'Measured as count of participants.'}, {'measure': 'Number of participants with achievement of >= 15% body weight reduction', 'timeFrame': 'From baseline (week 0) to end of treatment (week 64)', 'description': 'Measured as count of participants.'}, {'measure': 'Change in waist circumference', 'timeFrame': 'From baseline (week 0) to end of treatment (week 64)', 'description': 'Measured as centimeter (cm).'}, {'measure': 'Ratio to baseline in lipids: triglycerides', 'timeFrame': 'From baseline (week 0) to end of treatment (week 64)', 'description': 'Measured as ratio.'}, {'measure': 'Ratio to baseline in high sensitivity C-reactive protein (hsCRP)', 'timeFrame': 'From baseline (week 0) to end of treatment (week 64)', 'description': 'Measured as ratio.'}, {'measure': 'Change in impact of weight on quality of life-lite clinical trials version (IWQOL-Lite-CT) physical function score', 'timeFrame': 'From baseline (week 0) to end of treatment (week 64)', 'description': 'Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. The physical function score ranges from 0-100.'}, {'measure': 'Change in body weight', 'timeFrame': 'From baseline (week 0) to end of treatment (week 64)', 'description': 'Measured as kilogram (kg).'}, {'measure': 'Change in SF-36v2® health survey acute (SF-36v2® acute) physical component summary score', 'timeFrame': 'From baseline (week 0) to end of treatment (week 64)', 'description': 'Measured as score on a scale. SF-36v2 Acute measures Health-Related Quality of Life (HRQoL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. The physical component summary score ranges from 6.1 to 79.7.'}, {'measure': 'Change in SF-36v2® mental component summary score', 'timeFrame': 'From baseline (week 0) to end of treatment (week 64)', 'description': 'Measured as score on a scale. SF-36v2 Acute measures Health-Related Quality of Life (HRQoL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. The mental component summary score ranges from -3.8 to 78.7.'}, {'measure': 'Change in IWQOL-Lite-CT total score', 'timeFrame': 'From baseline (week 0) to end of treatment (week 64)', 'description': 'Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. The total score ranges from 0-100.'}, {'measure': 'Number of participants with achievement of at least 14.6-point increase in IWQOL-Lite-CT physical function score (yes/no)', 'timeFrame': 'From baseline (week 0) to end of treatment (week 64)', 'description': 'Measured as count of participants. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. The physical function score ranges from 0-100.'}, {'measure': 'Change in systolic blood pressure (SBP)', 'timeFrame': 'From baseline (week 0) to end of treatment (week 64)', 'description': 'Measured as millimeter of mercury (mmHg).'}, {'measure': 'Change in diastolic blood pressure (DBP)', 'timeFrame': 'From baseline (week 0) to end of treatment (week 64)', 'description': 'Measured as mmHg.'}, {'measure': 'Ratio to baseline in lipids: total cholesterol', 'timeFrame': 'From baseline (week 0) to end of treatment (week 64)', 'description': 'Measured as ratio.'}, {'measure': 'Ratio to baseline in lipids: high-density lipoprotein (HDL) cholesterol', 'timeFrame': 'From baseline (week 0) to end of treatment (week 64)', 'description': 'Measured as ratio.'}, {'measure': 'Ratio to baseline in lipids: low-density lipoprotein (LDL) cholesterol', 'timeFrame': 'From baseline (week 0) to end of treatment (week 64)', 'description': 'Measured as ratio.'}, {'measure': 'Ratio to baseline in lipids: very low-density lipoprotein (VLDL) cholesterol', 'timeFrame': 'From baseline (week 0) to end of treatment (week 64)', 'description': 'Measured as ratio.'}, {'measure': 'Ratio to baseline in lipids: non-HDL cholesterol', 'timeFrame': 'From baseline (week 0) to end of treatment (week 64)', 'description': 'Measured as ratio.'}, {'measure': 'Ratio to baseline in lipids: free fatty acids', 'timeFrame': 'From baseline (week 0) to end of treatment (week 64)', 'description': 'Measured as ratio.'}, {'measure': 'Change in glycated haemoglobin (HbA1c) in percentage-points (%-points)', 'timeFrame': 'From baseline (week 0) to end of treatment (week 64)', 'description': 'Measured as %-points.'}, {'measure': 'Change in HbA1c in millimole per mole (mmol/mol)', 'timeFrame': 'From baseline (week 0) to end of treatment (week 64)', 'description': 'Measured as mmol/mol.'}, {'measure': 'Change in fasting plasma glucose (FPG) in millimole per liter (mmol/L)', 'timeFrame': 'From baseline (week 0) to end of treatment (week 64)', 'description': 'Measured as mmol/L.'}, {'measure': 'Change in FPG in milligram per deciliter (mg/dL)', 'timeFrame': 'From baseline (week 0) to end of treatment (week 64)', 'description': 'Measured as mg/dL.'}, {'measure': 'Ratio to baseline in fasting serum insulin', 'timeFrame': 'From baseline (week 0) to end of treatment (week 64)', 'description': 'Measured as ratio.'}, {'measure': 'Number of treatment emergent adverse events', 'timeFrame': 'From baseline (week 0) to end of study (week 71)', 'description': 'Measured as count of events.'}, {'measure': 'Number of treatment emergent serious adverse events (TESAEs)', 'timeFrame': 'From baseline (week 0) to end of study (week 71)', 'description': 'Measured as count of events.'}, {'measure': 'Number of clinically significant hypoglycaemic episodes (level 2):<3.0 mmol/L [54 mg/dL], confirmed by blood glucose meter', 'timeFrame': 'From baseline (week 0) to end of study (week 71)', 'description': 'Measured as count of events.'}, {'measure': 'Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold', 'timeFrame': 'From baseline (week 0) to end of study (week 71)', 'description': 'Measured as count of events.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Overweight', 'Obesity', 'Type 2 Diabetes']}, 'descriptionModule': {'briefSummary': 'This study will look at how much cagrilintide helps people with overweight or obesity and type 2 diabetes lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participant will either get cagrilintide or placebo. Which treatment participant get is decided by chance. Participants are two times more likely to get cagrilintide than placebo. Like all medicines, the study medicine may have side effects. For each participant, the study will last for about 1 year and 6 months.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Key Inclusion Criteria:\n\n* Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.\n* Female or male (sex at birth).\n* Age 18 years or above at the time of signing the informed consent.\n* History of at least one self-reported unsuccessful dietary effort to lose body weight.(a\\*)\n* Body mass index (BMI) \\>= 27.0 kilogram per square meter (kg/m\\^2).(a\\*)\n* Diagnosed with type 2 diabetes \\>= 180 days before screening.\n* Treatment with either lifestyle intervention(a\\*), or:\n\n * Stable treatment (same drug(s), dose and dosing frequency) for at least 90 days before screening with 1-3 marketed oral antidiabetic drugs (metformin, α-glucosidase inhibitors (AGI), glinides, sodium-glucose cotransporter 2 inhibitor (SGLT2i), thiazolidinediones, Dipeptidyl peptidase-4 inhibitor (DPP-4i) or sulphonylureas (SU) as a single agent or in combination according to local practice.(a\\*)\n * For up to 30% of participants the following concomitant medication is allowed:\n\n * Treatment for any indication with a stable dose of glucagon-like peptide-1 (GLP-1) containing medication, stable for at least 1 year before screening (a\\*) and/or\n * Treatment with basal insulin minimum (0.25 units per kilogram per day (U/kg/day) or 20 units per day \\[U/day\\]) stable for at least 90 days before screening.(a\\*)\n\nKey Exclusion Criteria:\n\n* Treatment, or intention to initiate treatment, with any medication prescribed for the indication of weight management within 180 days before screening.(a\\*)\n* Treatment with glucagon-like peptide-1 (GLP-1) receptor agonist (RA) or GLP-1 containing medication within 180 days before screening, apart from those randomized according to inclusion criteria 7bi.(a\\*)\n* Previous dosing of marketed or non-marketed amylin-based compounds.(a\\*) (a\\*) - As declared by the participant, reported in the medical records or at the investigator's discretion."}, 'identificationModule': {'nctId': 'NCT07220759', 'acronym': 'RENEW 2', 'briefTitle': 'Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide', 'organization': {'class': 'INDUSTRY', 'fullName': 'Novo Nordisk A/S'}, 'officialTitle': 'Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or Obesity and Type 2 Diabetes', 'orgStudyIdInfo': {'id': 'NN9833-8243'}, 'secondaryIdInfos': [{'id': 'U1111-1314-9328', 'type': 'OTHER', 'domain': 'World Health Organization (WHO)'}, {'id': '2024-519531-41', 'type': 'OTHER', 'domain': 'European Medical Agency (EMA)'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Cagrilintide', 'description': 'Participants will receive cagrilintide subcutaneously once weekly for 64 weeks.', 'interventionNames': ['Drug: Cagrilintide']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'description': 'Participants will receive placebo matched to cagrilintide subcutaneously once weekly for 64 weeks.', 'interventionNames': ['Drug: Placebo (matched to Cagrilintide)']}], 'interventions': [{'name': 'Cagrilintide', 'type': 'DRUG', 'description': 'Cagrilintide will be administered subcutaneously with a pen-injector as an adjunt to lifestyle intervention counselling.', 'armGroupLabels': ['Cagrilintide']}, {'name': 'Placebo (matched to Cagrilintide)', 'type': 'DRUG', 'description': 'Placebo matched to cagrilintide will be administered subcutaneously with a pen-injector as an adjunt to lifestyle intervention counselling.', 'armGroupLabels': ['Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '35294', 'city': 'Birmingham', 'state': 'Alabama', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Univ of Alabama_Birmingham', 'geoPoint': {'lat': 33.52066, 'lon': -86.80249}}, {'zip': '36106', 'city': 'Montgomery', 'state': 'Alabama', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Chambliss Clinical Trials, LLC', 'geoPoint': {'lat': 32.36681, 'lon': -86.29997}}, {'zip': '85704', 'city': 'Tucson', 'state': 'Arizona', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Elite Clinical Network - Tucson', 'geoPoint': {'lat': 32.22174, 'lon': -110.92648}}, {'zip': '92037', 'city': 'La Jolla', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Scripps Whittier Diabetes Inst', 'geoPoint': {'lat': 32.84727, 'lon': -117.2742}}, {'zip': '95648', 'city': 'Lincoln', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Clinical Trials Research', 'geoPoint': {'lat': 38.89156, 'lon': -121.29301}}, {'zip': '90720', 'city': 'Los Alamitos', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Pacific Clinical Studies', 'geoPoint': {'lat': 33.80307, 'lon': -118.07256}}, {'zip': '34746', 'city': 'Kissimmee', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Walgreens - Store 4442', 'geoPoint': {'lat': 28.30468, 'lon': -81.41667}}, {'zip': '32763', 'city': 'Orange City', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Optimal Research Sites', 'geoPoint': {'lat': 28.94888, 'lon': -81.29867}}, {'zip': '33024', 'city': 'Pembroke Pines', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Center for Diab,Obes & Metab', 'geoPoint': {'lat': 26.00315, 'lon': -80.22394}}, {'zip': '33409', 'city': 'West Palm Beach', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Palm Beach Research Center', 'geoPoint': {'lat': 26.71534, 'lon': -80.05337}}, {'zip': '96814', 'city': 'Honolulu', 'state': 'Hawaii', 'status': 'COMPLETED', 'country': 'United States', 'facility': 'East West Med Res Inst', 'geoPoint': {'lat': 21.30694, 'lon': -157.85833}}, {'zip': '47714', 'city': 'Evansville', 'state': 'Indiana', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'MediSphere Medical RC', 'geoPoint': {'lat': 37.97476, 'lon': -87.55585}}, {'zip': '89146', 'city': 'Las Vegas', 'state': 'Nevada', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Walgreens - Store 3915', 'geoPoint': {'lat': 36.17497, 'lon': -115.13722}}, {'zip': '10455', 'city': 'The Bronx', 'state': 'New York', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Chear Center LLC', 'geoPoint': {'lat': 40.84985, 'lon': -73.86641}}, {'zip': '28562', 'city': 'New Bern', 'state': 'North Carolina', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Centricity Res New Bern', 'geoPoint': {'lat': 35.10849, 'lon': -77.04411}}, {'zip': '28401', 'city': 'Wilmington', 'state': 'North Carolina', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Accellacare', 'geoPoint': {'lat': 34.23556, 'lon': -77.94604}}, {'zip': '29303', 'city': 'Spartanburg', 'state': 'South Carolina', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Spartanburg Medical Research', 'geoPoint': {'lat': 34.94957, 'lon': -81.93205}}, {'zip': '37620', 'city': 'Bristol', 'state': 'Tennessee', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Holston Medical Group_Bristol', 'geoPoint': {'lat': 36.59511, 'lon': -82.18874}}, {'zip': '75230', 'city': 'Dallas', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Velocity Clinical Res-Dallas', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '23606', 'city': 'Newport News', 'state': 'Virginia', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'TPMG Clinical Research', 'geoPoint': {'lat': 36.98038, 'lon': -76.42975}}, {'zip': '23294', 'city': 'Richmond', 'state': 'Virginia', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'National Clin Res Inc.', 'geoPoint': {'lat': 37.55376, 'lon': -77.46026}}, {'zip': 'C1061AAE', 'city': 'Ciudad Autonoma de Buenos Aires', 'state': 'Buenos Aires', 'status': 'RECRUITING', 'country': 'Argentina', 'facility': 'Buenos Aires Mácula'}, {'zip': 'C1405BUB', 'city': 'Ciudad Autonoma de Buenos Aires', 'state': 'Buenos Aires', 'status': 'RECRUITING', 'country': 'Argentina', 'facility': 'CICEMO- Consultorio de Investigación Clínica EMO'}, {'zip': 'C1425AGC', 'city': 'Buenos Aires', 'status': 'RECRUITING', 'country': 'Argentina', 'facility': 'Centro Medico Dra. Laura Maffei e Investigacion Clínica Apli', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'zip': 'V1Y 1Z9', 'city': 'Kelowna', 'state': 'British Columbia', 'status': 'RECRUITING', 'country': 'Canada', 'facility': 'OCT Research ULC (dba Okanagan Clinical Trials)', 'geoPoint': {'lat': 49.88307, 'lon': -119.48568}}, {'zip': 'E1G 1A7', 'city': 'Moncton', 'state': 'New Brunswick', 'status': 'RECRUITING', 'country': 'Canada', 'facility': 'G.A. Research Associates Ltd.', 'geoPoint': {'lat': 46.09454, 'lon': -64.7965}}, {'zip': 'B3H 1V7', 'city': 'Halifax', 'state': 'Nova Scotia', 'status': 'RECRUITING', 'country': 'Canada', 'facility': 'Nova Scotia Hlth Halifax', 'geoPoint': {'lat': 44.64269, 'lon': -63.57688}}, {'zip': 'L6S 0C6', 'city': 'Brampton', 'state': 'Ontario', 'status': 'RECRUITING', 'country': 'Canada', 'facility': 'Centricity Research Brampton Endocrinology', 'geoPoint': {'lat': 43.68341, 'lon': -79.76633}}, {'zip': 'L8L 5G4', 'city': 'Hamilton', 'state': 'Ontario', 'status': 'RECRUITING', 'country': 'Canada', 'facility': 'Hamilton Medical Rsrch Grp', 'geoPoint': {'lat': 43.25011, 'lon': -79.84963}}, {'zip': 'L8L 5G8', 'city': 'Hamilton', 'state': 'Ontario', 'status': 'RECRUITING', 'country': 'Canada', 'facility': 'Wharton Med Clin Trials', 'geoPoint': {'lat': 43.25011, 'lon': -79.84963}}, {'zip': 'N5W 6A2', 'city': 'London', 'state': 'Ontario', 'status': 'RECRUITING', 'country': 'Canada', 'facility': 'Milestone Research', 'geoPoint': {'lat': 42.98339, 'lon': -81.23304}}, {'zip': 'H9R 4S3', 'city': 'Pointe-Claire', 'state': 'Quebec', 'status': 'RECRUITING', 'country': 'Canada', 'facility': 'Centricity Res Pointe-Claire', 'geoPoint': {'lat': 45.44868, 'lon': -73.81669}}, {'zip': 'G6P 3Z8', 'city': 'Victoriaville', 'state': 'Quebec', 'status': 'RECRUITING', 'country': 'Canada', 'facility': 'Diex Recherche Victoriaville', 'geoPoint': {'lat': 46.05007, 'lon': -71.96579}}, {'zip': '47000', 'city': 'Karlovac', 'status': 'RECRUITING', 'country': 'Croatia', 'facility': 'Opca bolnica Karlovac', 'geoPoint': {'lat': 45.49167, 'lon': 15.55}}, {'zip': '47000', 'city': 'Karlovac', 'status': 'NOT_YET_RECRUITING', 'country': 'Croatia', 'facility': 'Opca bolnica Karlovac', 'geoPoint': {'lat': 45.49167, 'lon': 15.55}}, {'zip': '49217', 'city': 'Krapinske Toplice', 'status': 'RECRUITING', 'country': 'Croatia', 'facility': 'Specijalna Bolnica za medicinsku rehabilitaciju Krapinske Toplice_Endocrinology', 'geoPoint': {'lat': 46.09333, 'lon': 15.84333}}, {'zip': '31000', 'city': 'Osijek', 'status': 'RECRUITING', 'country': 'Croatia', 'facility': 'Poliklinika SLAVONIJA OSIJEK', 'geoPoint': {'lat': 45.55066, 'lon': 18.6942}}, {'zip': '10000', 'city': 'Zagreb', 'status': 'RECRUITING', 'country': 'Croatia', 'facility': 'Poliklinika Solmed', 'geoPoint': {'lat': 45.81444, 'lon': 15.97798}}, {'zip': '10000', 'city': 'Zagreb', 'status': 'NOT_YET_RECRUITING', 'country': 'Croatia', 'facility': 'Poliklinika Solmed', 'geoPoint': {'lat': 45.81444, 'lon': 15.97798}}, {'zip': '370 11', 'city': 'České Budějovice', 'status': 'RECRUITING', 'country': 'Czechia', 'facility': 'Lékařský dům Géčko', 'geoPoint': {'lat': 48.97447, 'lon': 14.47434}}, {'zip': '149 00', 'city': 'Prague', 'status': 'RECRUITING', 'country': 'Czechia', 'facility': 'Milan Kvapil s.r.o.', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '150 00', 'city': 'Prague', 'status': 'RECRUITING', 'country': 'Czechia', 'facility': 'EUC Klinika Praha a.s.', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '4032', 'city': 'Debrecen', 'state': 'Hajdú-Bihar', 'status': 'RECRUITING', 'country': 'Hungary', 'facility': 'Debreceni Egyetem', 'geoPoint': {'lat': 47.53167, 'lon': 21.62444}}, {'zip': '1036', 'city': 'Budapest', 'state': 'Pest County', 'status': 'RECRUITING', 'country': 'Hungary', 'facility': 'QUALICLINIC Egészségügyi Szolgáltató és Kutatásszervező Kft'}, {'zip': '1036', 'city': 'Budapest', 'state': 'Pest County', 'status': 'RECRUITING', 'country': 'Hungary', 'facility': 'Óbudai Egészségügyi Centrum'}, {'zip': '2900', 'city': 'Komárom', 'status': 'RECRUITING', 'country': 'Hungary', 'facility': 'Komáromi Selye János Kórház', 'geoPoint': {'lat': 47.74318, 'lon': 18.11913}}, {'zip': '100179', 'city': 'Ploieşti', 'state': 'Prahova', 'status': 'RECRUITING', 'country': 'Romania', 'facility': 'Diabmed Dr Popescu Alexandrina SRL', 'geoPoint': {'lat': 44.95, 'lon': 26.01667}}, {'zip': '600154', 'city': 'Bacau', 'status': 'RECRUITING', 'country': 'Romania', 'facility': 'CMI Dr. Pletea Noemi SRL', 'geoPoint': {'lat': 46.56718, 'lon': 26.91384}}, {'zip': '050913', 'city': 'Bucharest', 'status': 'RECRUITING', 'country': 'Romania', 'facility': 'Diabet Med SRL', 'geoPoint': {'lat': 44.43225, 'lon': 26.10626}}, {'zip': '800001', 'city': 'Galati', 'status': 'RECRUITING', 'country': 'Romania', 'facility': 'S.C Milena Sante SRL', 'geoPoint': {'lat': 45.43687, 'lon': 28.05028}}, {'zip': '440055', 'city': 'Satu Mare', 'status': 'RECRUITING', 'country': 'Romania', 'facility': 'Clinica Korall S.R.L. Satu Mare', 'geoPoint': {'lat': 47.79926, 'lon': 22.86255}}, {'zip': '831 01', 'city': 'Bratislava', 'status': 'RECRUITING', 'country': 'Slovakia', 'facility': 'Nemocnica akademika L. Derera, UNB', 'geoPoint': {'lat': 48.14816, 'lon': 17.10674}}, {'zip': '04801', 'city': 'Rožňava', 'status': 'RECRUITING', 'country': 'Slovakia', 'facility': 'DIAB s.r.o.', 'geoPoint': {'lat': 48.66009, 'lon': 20.53758}}, {'zip': '038 61', 'city': 'Vrútky', 'status': 'RECRUITING', 'country': 'Slovakia', 'facility': 'IRIDIA s.r.o.', 'geoPoint': {'lat': 49.11328, 'lon': 18.91714}}, {'zip': '50612', 'city': 'Yangsan', 'state': 'Gyeongsangnam-do', 'status': 'RECRUITING', 'country': 'South Korea', 'facility': 'Pusan National University Yangsan Hospital', 'geoPoint': {'lat': 35.34199, 'lon': 129.03358}}, {'zip': '61469', 'city': 'Gwangju', 'status': 'RECRUITING', 'country': 'South Korea', 'facility': 'Chonnam National University Hospital', 'geoPoint': {'lat': 35.15472, 'lon': 126.91556}}, {'zip': '03080', 'city': 'Seoul', 'status': 'RECRUITING', 'country': 'South Korea', 'facility': 'Seoul National University Hospital', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '06591', 'city': 'Seoul', 'status': 'RECRUITING', 'country': 'South Korea', 'facility': "The Catholic University of Korea, Seoul ST. Mary's Hospital", 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '07345', 'city': 'Seoul', 'status': 'RECRUITING', 'country': 'South Korea', 'facility': "The Catholic University of Korea, Yeouido ST. Mary's Hospital", 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '130-872', 'city': 'Seoul', 'status': 'RECRUITING', 'country': 'South Korea', 'facility': 'Kyunghee University Medical Center', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '4031', 'city': 'Basel', 'status': 'RECRUITING', 'country': 'Switzerland', 'facility': 'Universitätsspital Basel', 'geoPoint': {'lat': 47.55839, 'lon': 7.57327}}, {'zip': '1011', 'city': 'Lausanne', 'status': 'COMPLETED', 'country': 'Switzerland', 'facility': 'Centre hospitalier universitaire vaudois CHUV', 'geoPoint': {'lat': 46.516, 'lon': 6.63282}}, {'zip': '4600', 'city': 'Olten', 'status': 'RECRUITING', 'country': 'Switzerland', 'facility': 'Kantonsspital Olten', 'geoPoint': {'lat': 47.34999, 'lon': 7.90329}}, {'zip': '8125', 'city': 'Zollikerberg', 'status': 'RECRUITING', 'country': 'Switzerland', 'facility': 'Diabetes Adipositas Zentrum Zürich', 'geoPoint': {'lat': 47.3451, 'lon': 8.60088}}, {'zip': 'PL14 3XA', 'city': 'Liskeard', 'state': 'Cornwall', 'status': 'RECRUITING', 'country': 'United Kingdom', 'facility': 'Oak Tree Surgery', 'geoPoint': {'lat': 50.4545, 'lon': -4.46517}}, {'zip': 'TR7 1RU', 'city': 'Newquay', 'state': 'Cornwall', 'status': 'RECRUITING', 'country': 'United Kingdom', 'facility': 'North Coast Medical Ltd', 'geoPoint': {'lat': 50.41557, 'lon': -5.07319}}, {'zip': 'TQ1 4QX', 'city': 'Torquay', 'state': 'Devon', 'status': 'RECRUITING', 'country': 'United Kingdom', 'facility': 'Brunel Medical Practice', 'geoPoint': {'lat': 50.46198, 'lon': -3.52522}}, {'zip': 'WD23 2NN', 'city': 'Bushey', 'state': 'Hertfordshire', 'status': 'RECRUITING', 'country': 'United Kingdom', 'facility': 'Attenborough Surgery', 'geoPoint': {'lat': 51.64316, 'lon': -0.36053}}, {'zip': 'W6 7HY', 'city': 'London', 'status': 'RECRUITING', 'country': 'United Kingdom', 'facility': 'Hammersmith and Fulham Partnership Research Unit - Richford Gate Primary Care Centre', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}], 'centralContacts': [{'name': 'Novo Nordisk', 'role': 'CONTACT', 'email': 'clinicaltrials@novonordisk.com', 'phone': '(+1) 866-867-7178'}], 'overallOfficials': [{'name': "Clinical Transparency' (dept. 2834)", 'role': 'STUDY_DIRECTOR', 'affiliation': 'Novo Nordisk A/S'}]}, 'ipdSharingStatementModule': {'url': 'https://novonordisk-trials.com', 'ipdSharing': 'YES', 'description': 'According to the Novo Nordisk disclosure commitment on novonordisk-trials.com'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Novo Nordisk A/S', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}